Metastatic human prostate cancer cells transplanted into a mouse self-destruct (red) when treated with ISRIB, an experimental drug that exposes cancer cells to their full, unhealthy appetite for protein synthesis.
Davide Ruggero, PhD, the Helen Diller Family Chair in Basic Cancer Research and a professor of urology and cellular and molecular pharmacology at UCSF and paper's senior author.